Related topics:
Pharmaceutical/Biotech, Europe, Market Access & HEOR, Biosimilars
Availability: FREE
How the complex characteristics of biologics (and biosimilars) contribute to perceived value to different stakeholders.
The salient issues facing Upstarts (marketers of biosimilars) and Defenders (marketers of “original” biologics) in communicating comparative worth to stakeholders.
How MCDA modelling methods can assist both groups in better defining and communicating value.
Speaker
Mason W. Russell
Vice President, Strategic Consulting (Life Sciences) Truven, USA